A61K 51/1039
Against t-cell receptors
Official title: {against T-cell receptors}
A61K51/1039 (Against t-cell receptors) appears on 41 US grants and 45 published applications in this corpus.
Search patents in A61K- Granted patents
- 41
- Published applications
- 45
- Assignees
- 33
- Inventors
- 127
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 3 | 0 |
| 2002 | 3 | 1 |
| 2003 | 4 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 3 |
| 2006 | 0 | 1 |
| 2007 | 1 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 2 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 1 | 6 |
| 2019 | 0 | 3 |
| 2020 | 3 | 4 |
| 2021 | 4 | 2 |
| 2022 | 2 | 4 |
| 2023 | 1 | 3 |
| 2024 | 2 | 4 |
| 2025 | 2 | 3 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Radiolabeled anti-LAG3 antibodies for immuno-PET imaging1 Sep 2026US 12,721,914 B2Regeneron Pharmaceuticals, Inc.
- CD8 binding agents and uses thereof25 Aug 2026US 12,715,920 B2Genentech, Inc.
- Radioconjugates directed to MHC-complexed antigens in cancer21 Oct 2025US 12,447,218 B1
- Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion5 Aug 2025US 12,377,143 B2Chugai Seiyaku Kabushiki Kaisha
- Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation17 Sep 2024US 12,091,460 B2Regeneron Pharmaceuticals, Inc.
- Anti-her2/cd3 bispecific antibody specifically activated in tumor microenvironment3 Sep 2026US 2026/0258127 A1Ying Mai De Medical Technology (Guangdong) Co., Ltd.
- Cd3 targeting antibodies and uses thereof6 Nov 2025US 2025/0340637 A1Abpro Corporation
- Agents for treatment of endometriosis and other benign gynecological neoplasms24 Jul 2025US 2025/0235567 A1UniversitäT ZüRich
- Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation6 Feb 2025US 2025/0042999 A1Regeneron Pharmaceuticals, Inc.
- Anti-tigit antibody and use thereof24 Oct 2024US 2024/0352118 A1Biotheus Inc.
Most cited
By later US patents
- Lymphographic and organ imaging method and kit129US 5,101,827 AImmunomedics, Inc. · 1992
- Method for imaging and treating organs and tissues124US 5,697,902 AImmunomedics, Inc. · 1997
- Method and kit for imaging and treating organs and tissues110US 6,331,175 B1Immunomedics, Inc. · 2001
- Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same71US 5,474,771 AThe Trustees of Columbia University in the City of New York · 1995
- Treatment of CD4 T-cell mediated conditions70US 5,759,546 A1998